Induction therapies in live donor kidney transplantation on tacrolimus and mycophenolate with or without steroid maintenance

Clinical Journal of the American Society of Nephrology

Volumn 10, Issue 6, 2015, Pages 1041-1049

  Tanriover, Bekir ^a   Zhang, Song ^b   MacConmara, Malcolm ^b   Gao, Ang ^b   Sandikci, Burhaneddin ^c   Ayvaci, Mehmet U S ^d   Mete, Mutlu ^e   Tsapepas, Demetra ^f   Rajora, Nilum ^a   Mohan, Prince ^g   Lakhia, Ronak ^a   Lu, Christopher Y ^a   Vazquez, Miguel ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF TEXAS AT DALLAS   (United States)

^e TEXAS A AND M UNIVERSITY   (United States)

^f NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Acute allograft rejection; Immunosuppression; Kidney transplantation

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CD45 ANTIGEN; CYTOKINE RECEPTOR ANTAGONIST; INTERLEUKIN 2 RECEPTOR ANTAGONIST; MYCOPHENOLIC ACID; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; CALCINEURIN INHIBITOR; CD52 ANTIGEN; GLYCOPROTEIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR; LEUKOCYTE ANTIGEN; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ADULT; ARTICLE; BIOPSY; CONTROLLED STUDY; DIALYSIS; DRUG EFFICACY; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT REJECTION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PROPENSITY SCORE; TREATMENT OUTCOME; ACUTE DISEASE; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG EFFECTS; GRAFT SURVIVAL; IMMUNOLOGY; KAPLAN MEIER METHOD; LIVING DONOR; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROCEDURES; PROPORTIONAL HAZARDS MODEL; REGISTER; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; TRANSPLANTATION;

ACUTE DISEASE; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTILYMPHOCYTE SERUM; CALCINEURIN INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; GLYCOPROTEINS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; LIVING DONORS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOPHENOLIC ACID; ODDS RATIO; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RECEPTORS, INTERLEUKIN-2; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; STEROIDS; TACROLIMUS; TIME FACTORS; TISSUE AND ORGAN PROCUREMENT; TREATMENT OUTCOME;

EID: 84930419762     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.08710814     Document Type: Article

References (36)

1. Kidney Disease Improving Global Outcomes Transplant Work Group: KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9[Suppl 3]: S1-S155, 2009
2. Bia M, Adey DB, Bloom RD, Chan L, Kulkarni S, Tomlanovich S: KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients.AmJ Kidney Dis 56: 189-218, 2010
3. Silva HT Jr, Yang HC, Abouljoud M, Kuo PC, Wisemandle K, Bhattacharya P, Dhadda S, Holman J, Fitzsimmons W, First MR: One-year results with extended-release tacrolimus/MMF, tacrolimus/ MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant 7: 595-608, 2007
4. Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, Margreiter R, Hugo C, Grinyó JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF; ELITE-Symphony Study: Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 357: 2562-2575, 2007
5. Matas AJ, Smith JM, Skeans MA, Thompson B, Gustafson SK, Schnitzler MA, Stewart DE, CherikhWS,Wainright JL, Snyder JJ, Israni AK, Kasiske BL: OPTN/SRTR 2012 Annual Data Report: Kidney. Am J Transplant 14[Suppl 1]: 11-44, 2014
6. Hardinger KL, Brennan DC, Klein CL: Selection of induction therapy in kidney transplantation. Transpl Int 26: 662-672, 2013
7. Ahsan N, Holman MJ, Jarowenko MV, Razzaque MS, Yang HC: Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. Am J Transplant 2: 568-573, 2002
8. Woodle ES, Peddi VR, Tomlanovich S, Mulgaonkar S, Kuo PC; TRIMS Study Investigators: A prospective, randomized, multicenter study evaluating early corticosteroid withdrawal with thymoglobulin in living-donor kidney transplantation. Clin Transplant 24: 73-83, 2010
9. Gralla J, Wiseman AC: The impact of IL2ra induction therapy in kidney transplantation using tacrolimus- and mycophenolatebased immunosuppression. Transplantation 90: 639-644, 2010
10. Willoughby LM, Schnitzler MA, Brennan DC, Pinsky BW, Dzebisashvili N, Buchanan PM, Neri L, Rocca-Rey LA, Abbott KC, Lentine KL: Early outcomes of thymoglobulin and basiliximab induction in kidney transplantation: Application of statistical approaches to reduce bias in observational comparisons. Transplantation 87: 1520-1529, 2009
11. Webster AC, Playford EG, Higgins G, Chapman JR, Craig J: Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev (1): CD003897, 2004
12. Spreeuwenberg MD, Bartak A, Croon MA, Hagenaars JA, Busschbach JJ, Andrea H, Twisk J, Stijnen T: The multiple propensity score as control for bias in the comparison of more than two treatment arms: An introduction from a case study in mental health. Med Care 48: 166-174, 2010
13. Rubin DB, Thomas N: Matching using estimated propensity scores: Relating theory to practice. Biometrics 52: 249-264, 1996
14. D'Agostino RB Jr: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17: 2265-2281, 1998
15. Kurth T, Walker AM, Glynn RJ, Chan KA, Gaziano JM, Berger K, Robins JM: Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniformeffect.AmJ Epidemiol 163: 262-270, 2006
16. Emami S, Huang E, Kuo HT, Kamgar M, Bunnapradist S: Multivariate analysis of antibody induction therapy and their associated outcomes in live donor kidney transplantation in the recent era. Clin Transplant 26: 351-358, 2012
17. Amico P, Hönger G, Mayr M, Steiger J, Hopfer H, Schaub S: Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 87: 1681-1688, 2009
18. Vaidya S, Partlow D, Susskind B, NoorM, Barnes T, Gugliuzza K: Prediction of crossmatch outcome of highly sensitized patients by single and/or multiple antigen bead Luminex assay. Transplantation 82: 1524-1528, 2006
19. Cecka JM, Kucheryavaya AY, Reinsmoen NL, Leffell MS: Calculated PRA: Initial results show benefits for sensitized patients and a reduction in positive crossmatches. Am J Transplant 11: 719-724, 2011
20. Mulley WR, Kanellis J: Understanding crossmatch testing in organ transplantation: A case-based guide for the general nephrologist. Nephrology (Carlton) 16: 125-133, 2011
21. Bryan CF, Baier KA,NelsonPW, Luger AM, Martinez J, PierceGE, Ross G, Shield CF 3rd,Warady BA, Aeder MI,Helling TS,Muruve N: Long-term graft survival is improved in cadaveric renal retransplantation by flow cytometric crossmatching. Transplantation 66: 1827-1832, 1998
22. BielmannD, Hönger G, Lutz D, Mihatsch MJ, Steiger J, Schaub S: Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am J Transplant 7: 626-632, 2007
23. Bingaman AW, Murphey CL, Palma-Vargas J, Wright F: A virtual crossmatch protocol significantly increases access of highly sensitized patients to deceased donor kidney transplantation. Transplantation 86: 1864-1868, 2008
24. Webster AC, Playford EG, Higgins G, Chapman JR, Craig J: Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev (1): CD003897, 2010
25. Ahsan N, Hricik D, Matas A, Rose S, Tomlanovich S,Wilkinson A, Ewell M, McIntosh M, Stablein D, Hodge E; Steroid Withdrawal Study Group: Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil-a prospective randomized study. Transplantation 68: 1865-1874, 1999
26. Vanrenterghem Y, Lebranchu Y, Hené R, Oppenheimer F, Ekberg H: Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 70: 1352-1359, 2000
27. Kasiske BL, Chakkera HA, Louis TA, Ma JZ: A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 11: 1910-1917, 2000
28. Vincenti F, Schena FP, Paraskevas S, Hauser IA, Walker RG, Grinyo J; FREEDOM Study Group: A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients.AmJ Transplant 8: 307-316, 2008
29. Woodle ES, Vincenti F, Lorber MI, Gritsch HA, Hricik D, Washburn K, Matas AJ, Gallichio M,Neylan J: Amulticenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus. Am J Transplant 5: 157-166, 2005
30. Heilman RL, Reddy KS, Mazur MJ, Moss AA, Post DJ, Petrides S, Mulligan DC: Acute rejection risk in kidney transplant recipients on steroid-avoidance immunosuppression receiving induction with either antithymocyte globulin or basiliximab. Transplant Proc 38: 1307-1313, 2006
31. Ciancio G, Gaynor JJ, Guerra G, Sageshima J, Chen L, Mattiazzi A, Roth D, Kupin W, Tueros L, Flores S, Hanson L, Vianna R, BurkeGW3rd: Randomized trial of three induction antibodies in kidney transplantation: Long-term results. Transplantation 97: 1128-1138, 2014
32. Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P; Astellas Corticosteroid Withdrawal Study Group: A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 248: 564-577, 2008
33. Pascual J, Royuela A, Galeano C, Crespo M, Zamora J: Very early steroid withdrawal or complete avoidance for kidney transplant recipients: A systematic review. Nephrol Dial Transplant 27: 825-832, 2012
34. HanawayMJ,Woodle ES, Mulgaonkar S, Peddi VR, Kaufman DB, First MR, Croy R, Holman J; INTAC Study Group: Alemtuzumab induction in renal transplantation. N Engl J Med 364: 1909- 1919, 2011
35. Sampaio MS, Kadiyala A, Gill J, Bunnapradist S: Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation. Transplantation 88: 904-910, 2009
36. LilliuH, Brun-Strang C, Le Pen C, BüchlerM, Al Najjar A, Priol G, Reigneau O, Lebranchu Y: Cost-minimization study comparing Simulect vs. thymoglobulin in renal transplant induction. Clin Transplant 18: 247-253, 2004